Le Lézard
Classified in: Health, Science and technology, Business
Subjects: PDT, ACC, VEN

Stockholm-based Technology Startup Sigrid Therapeutics Developing a Breakthrough Device to Lower Blood Sugar Levels, Closes Oversubscribed Round of $1.6m, Bringing Total Pre-launch Funding to $9m

STOCKHOLM, Sept. 5, 2019 /PRNewswire/ -- Sigrid Therapeutics AB, an innovative technology company developing a new class of products to improve human health, including type 2 diabetes, today announces an equity financing round of USD 1.6M. The two times oversubscribed financing round was led by Joyance Partners, a US-based venture capital firm, and Pär Gellerfors, one of the founders of the biotechnology company BioArctic, listed on Nasdaq Stockholm.

Sigrid Therapeutics' lead product, SiPore15, is an orally-administered medical device consisting of precisely engineered micron-sized silica particles with tailored porosity designed to act locally in the gut. Upon its approval, SiPore15 will be the first and only oral product of its kind for reduction of blood sugar levels in people at risk of developing type 2 diabetes and newly diagnosed type 2 diabetics.

"Sigrid Therapeutics is an extremely exciting company with an exceptional team," says Pär Gellerfors, member of the Board of Directors. "With its forthcoming results from the STAR clinical trial, I am confident that the Sigrid team will continue to deliver on its progress towards a novel product for type 2 diabetes," continues Pär Gellerfors.

Joyance Partners, a San-Francisco based venture capital fund focusing on the emerging science of health and happiness, has recently expanded their investment horizon and presence to Europe. "Health and happiness exist in a continuum. Greater health unlocks the potential for happiness. Sigrid Therapeutics perfectly embodies this principle: the Company's lead product SiPore15tm safely reduces blood sugar levels, which results in less worries and happier lives for individuals at risk of developing diabetes or already afflicted by the disease. We couldn't have found a better partner to start our journey in the Nordics," says Paolo Pio, Managing Director of Joyance Partners, Europe.

Sigrid Therapeutics' CEO, Sana Alajmovic comments: "I am thrilled that this financing round created such great interest among so many seasoned investors. The new funds will provide us with resources to expand on SiPore15tm's clinical development plans, as we prepare for market registration in EU."

For more information, please contact:

Sana Alajmovic, Co-Founder & CEO, Sigrid Therapeutics
Phone +46 72 389 3396,
Email: sana@sigridthx.com  


SOURCE Sigrid Therapeutics

These press releases may also interest you

at 19:40
Working Opportunity Fund (EVCC) Ltd. ("WOF" or the "Fund") provides a portfolio update. The Fund is actively working with the management teams of portfolio companies to support them in working through the challenges brought on by the COVID-19...

at 19:20
Jason Industries, Inc. ("Jason" or the "Company") today announced that it has entered into a restructuring support agreement (the "Agreement") with certain of its senior secured lenders. The Agreement outlines a comprehensive restructuring plan that...

at 18:55
The Board of Directors of PNM, a subsidiary of PNM Resources , declared the regular quarterly dividend of $1.145 per share on the 4.58 percent series of cumulative preferred stock. The preferred stock dividend is payable July 15, 2020 to shareholders...

at 18:35
EarthRenew Inc. ("EarthRenew" or the "Company") has granted a total of 3,500,000 stock options to certain officers, directors, employees and consultants of the Company pursuant to the Company's stock option plan. The stock options vest immediately...

at 18:10
Solar Alliance Energy Inc. (?Solar Alliance' or the ?Company') announces that it has settled and extinguished $111,436.50 of the Company's outstanding debt (the "Debt") through the issuance of common shares of the Company ("Common Shares"). In...

at 18:05
Euro Tech Holdings Company Limited today reported financial results for the 12-month period ended December 31, 2019 ("Fiscal 2019"). The Company's revenues for Fiscal 2019 were approximately US$17,399,000, an approximate 13.5% decrease compared to...

News published on 5 september 2019 at 03:00 and distributed by: